Neoleukin Therapeutics, Inc. logo

Neoleukin Therapeutics, Inc.

NASDAQ:NLTX

Overview | Financials
Company Name Neoleukin Therapeutics, Inc.
Symbol NLTX
Currency USD
Price 3.49
Market Cap 8,199,685
Dividend Yield 0%
52-week-range 3.42 - 18.8
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Ms. Donna M. Cochener-Metcalfe J.D.
Website https://www.neoleukin.com

An error occurred while fetching data.

About Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal

Related Stocks

IN8bio, Inc. logo

IN8bio, Inc.

INAB

1 USD

Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc.

SPRO

1.5 USD

Ocuphire Pharma, Inc. logo

Ocuphire Pharma, Inc.

OCUP

1.74 USD

Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc.

COCP

1.43 USD

Financials

Numbers are in millions USD

Numbers are in millions USD